Molecular genetic analysis of haematological malignancies II: mature lymphoid neoplasms

Bench, Anthony J.; Erber, Wendy N.; Follows, George; Scott, Mike

doi:10.1111/j.1751-553x.2007.00876.x

Cited by 25 publications

(18 citation statements)

References 317 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TCRα/δ-TCL1α, TCRα/δ-TCL1β, TCRα/δ-MTCP1, TCRα/δ-MTCP1 Гиперэкспрессия протоонкогенов ТСL1, MTCP1, приводящая к активации сигнального пути Akt [69][70][71] Лимфолейкоз из крупных гранулярных клеток Заболевание сопровождается клональной пролиферацией цитотоксических Т-клеток -крупных гранулярных клеток, а также цитопенией. Характерных хромосомных аномалий не отмечено, могут присутствовать генетический нарушения, присущие классу Т-клеточных лимфом в целом (преимущественно, различные реаранжировки в гене TCR и связанные с ними нарушения сигнальных путей) [83]. Наблюдается активация множественных сигнальных путей, таких как JAK/STAT3, сфинголипидов и MEK/ERK, что приводит к подавлению апоптоза и устойчивости к нормальным путям активации индуцированной клеточной гибели [92] Агрессивный лейкоз из NK-клеток Реаранжировки TCR, IG Может наблюдаться гиперэкспрессия различных проонкогенов, характерных для Т-клеточных лейкозов/лимфом в целом [83,93].…”

Section: Cltc-alkunclassified

“…Характерных хромосомных аномалий не отмечено, могут присутствовать генетический нарушения, присущие классу Т-клеточных лимфом в целом (преимущественно, различные реаранжировки в гене TCR и связанные с ними нарушения сигнальных путей) [83]. Наблюдается активация множественных сигнальных путей, таких как JAK/STAT3, сфинголипидов и MEK/ERK, что приводит к подавлению апоптоза и устойчивости к нормальным путям активации индуцированной клеточной гибели [92] Агрессивный лейкоз из NK-клеток Реаранжировки TCR, IG Может наблюдаться гиперэкспрессия различных проонкогенов, характерных для Т-клеточных лейкозов/лимфом в целом [83,93]. Геномная потеря локуса CD58.…”

Section: Cltc-alkunclassified

“…CD58 -лиганд рецептора CD2, который экспрессируется на CTL-и NK-клетках и участвует в контроле адгезии и активации этих клеток [24,94] Т-клеточная лимфома/лейкоз взрослых (HTLV1+) 14q11.2, выявляют внедрение провирусного генома НTLV1, может встречаться add(7q) [83]. Более высокая частота хромосомных аномалий наблюдается в сегментах хромосом 1р, 3q, 6q, 9q, 12q, 14q [24,94] Реаранжировки TCR Т-клеточная лимфома, связанная с энтеропатией 14q11.2, 7р14 [83] Реаранжировки TCRδ, TCRγ…”

Section: Cltc-alkunclassified

“…Более высокая частота хромосомных аномалий наблюдается в сегментах хромосом 1р, 3q, 6q, 9q, 12q, 14q [24,94] Реаранжировки TCR Т-клеточная лимфома, связанная с энтеропатией 14q11.2, 7р14 [83] Реаранжировки TCRδ, TCRγ…”

Section: Cltc-alkunclassified

See 3 more Smart Citations

Molecular Genetic Abnormalities in the Pathogenesis of Hematologic Malignancies and Corresponding Changes in Cell Signaling Systems

Тилова¹,

Savinkova²,

Zhidkova³

et al. 2017

Клиническая онкогематология

View full text Add to dashboard Cite

Hematological disorders include a wide spectrum of malignancies of hematopoietic and lymphoid tissues. The genetic changes underlying the pathogenesis of the diseases are specific for each disease. High incidence of chromosomal aberrations (deletion, translocation, insertion) is one of the principal characteristics of oncohematological diseases. In addition, mutations in individual genes or blocking of normal regulation of gene functioning in relation to epigenetic events can occur. Progression of oncohematological diseases could be a result of accumulation of different genetic abnormalities. Modern classification of malignancies of hematopoietic and lymphoid tissues is based on the analysis of clinical data, morphological and functional characteristics of tumor cells and identification of specific cytogenetic and molecular-genetic changes. A large number of genetic abnormalities specific for certain types of hematological malignancies has been discovered to date. It allows to optimize the treatment strategy, as well as to design, test and introduce to the clinical practice a number of targeted drugs (inhibitors of chimeric proteins formed as a result of trans-locations and triggering the malignant cell transformation). Drugs based on monoclonal antibodies (Rituximab, Alemtuzumab, etc.) or low molecular weight compounds (Imatinib, Bortezomib, Carfilzomib) form this group of medications. The knowledge about not only specific gene abnormalities but also about the corresponding changes in cell efferent signaling pathways could be of great interest for the development of new targeted molecules or the repurposing of known chemotherapeutic agents. The present review compares genetic aberrations in diseases listed in the 2008 WHO classification (amended in 2016) of hematopoietic and lymphoid tissue malignancies and main changes in cell signaling pathways associated with malignant transformation of hematopoietic cells.

show abstract

Section: Cltc-alkunclassified

See 2 more Smart Citations

Molecular Genetic Abnormalities in the Pathogenesis of Hematologic Malignancies and Corresponding Changes in Cell Signaling Systems

Тилова¹,

Savinkova²,

Zhidkova³

et al. 2017

Клиническая онкогематология

View full text Add to dashboard Cite

show abstract

“…In 8 cases (3.4%) it was not possible to determine nodal or extranodal involvement. In the extranodal cases, the most common site of involvement was the gastrointestinal tract (59 cases); 49 cases were referred to as extranodal abdominal tumor without further specification; involvement of liver, oropharynx/nasopharynx, jaw/maxilla, ovaries, and central nervous system were observed in 7,6,5,4, and 2 cases, respectively. Among the patients with primary lymph node disease, the most common sites of involvement were the cervical region (32 cases) and the axilla (15 cases).…”

Section: Clinical Featuresmentioning

confidence: 99%

Linfoma de Burkitt: características clinicopatológicas, imunoistoquímicas e associação com o vírus de Epstein-Barr (EBV) em populações adulta e pediátrica em diferentes regiões geográficas no Brasil

Queiroga¹

View full text Add to dashboard Cite

Aos patologistas da Consultoria em Patologia, em especial à Dra. Sheila Wludarski e ao Dr. Lisandro Ferreira Lopes, pela convivência e aprendizado profissional. À Dra. Lucimara Chioato e à Dra. Luciana Hayashi, biólogas do Genepath, pela realização da PCR e hibridização "in situ". (Chuang et al., 2007; Rodig et al., 2008). É importante ressaltar que estudos têm demonstrado expressão variável de CD10, BCL-6 e, ainda, expressão aberrante de BCL-2 (Frost et al., 2004;Cogliati et al., 2006;Chuang et al., 2007;Chuang et al., 2008 (mais de 100 kb das seqüências codificatórias e regulatórias do gene) e a quebra no locus da IGH ocorre dentro do segmento J (região juncional). Nos LB esporádico e associado ao HIV o ponto de ruptura, em geral, ocorre entre os exons 1 e 2 do gene C-MYC e a junção no cromossomo 14 ocorre na região "switch" (Barriga et al., 1988;Shiramizu et al., 1991). Estes achados sugerem que a transformação neoplásica afeta células B em diferentes estágios de maturação (Shiramizu et al., 1991 de plasmócitos e células T ativadas (Tsuboi et al., 2000; Ponzoni et al., 2007;Naresh, 2007). A expressão de MUM1/IRF4 é restrita a células linfóides e melanocíticas (Natkunam et al., 2001; Ponzoni et al., 2007). Em tecido linfóide normal e reativo a expressão de MUM1/IRF4 é observada em plasmócitos, em uma pequena fração de células B localizadas na zona clara do centro germinativo (com morfologia de centrocito) e também em células T ativadas (Tsuboi et al., 2000; Falini et al., 2000). Carbone et al., 2000; Falini et al., 2000;Carbone et al., 2001;Natkunam et al., 2001; Vegga et al., 2004;Naresh, 2007). Em relação ao LB, os trabalhos iniciais analisam um número bastante limitado de casos (Tsuboi et al., 2000; Falini et al., 2000;Carbone et al., 2000;Natkunam et al., 2001).Recentemente, Chuang et al. (2007Chuang et al. ( , 2008 SP15-500). A leitura das reações foi realizada ao microscópio óptico comum.Células revelando positividade quanto à presença do EBV apresentam marcação nuclear, resultado da precipitação do cromógeno nos sítios de ligação da sonda ao RNA viral. Os controles positivos para a reação foram incluídos nos blocos de TMA e foram representados por um caso de linfoma de Hodgkin clássico e um caso de LB. ImunoistoquímicaPara a realização do estudo imunoistoquímico foram obtidos, de cada um dos blocos de TMA, cortes histológicos seriados com espessura (1996).Todas as reações foram analisadas em corrida eletroforética em gel de poliacrilamida 7% corado pelo método de impregnação pela prata. • Trato gastrintestinal • Ovário A figura 15 mostra também a distribuição segundo faixa etária (adulto e pediátrico) nos casos EBV positivos. Verificou-se que, em todas as regiões geográficas, com exceção da região Sul, houve predomínio de pacientes pediátricos entre os casos de LB associados ao EBV. Caracterização imunoistoquímicaTodos os 234 casos revelaram expressão para CD20, CD10, com índice de proliferação celular > 95%, determinado pela expressão do antígeno Ki-67, e negatividade para CD3, TdT ...

show abstract

The Molecular Pathology of Burkitt Lymphoma

Mosse

Weck

2010

Molecular Pathology Library

View full text Add to dashboard Cite

Molecular genetic analysis of haematological malignancies II: mature lymphoid neoplasms

Cited by 25 publications

References 317 publications

Molecular Genetic Abnormalities in the Pathogenesis of Hematologic Malignancies and Corresponding Changes in Cell Signaling Systems

Molecular Genetic Abnormalities in the Pathogenesis of Hematologic Malignancies and Corresponding Changes in Cell Signaling Systems

Linfoma de Burkitt: características clinicopatológicas, imunoistoquímicas e associação com o vírus de Epstein-Barr (EBV) em populações adulta e pediátrica em diferentes regiões geográficas no Brasil

The Molecular Pathology of Burkitt Lymphoma

Contact Info

Product

Resources

About